Frequency Therapeutics, Inc. – NASDAQ:FREQ
Founder-led company
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in 28 minutes
Frequency Therapeutics stock price monthly change
-15.99%
month
Frequency Therapeutics stock price quarterly change
-54.34%
quarter
Frequency Therapeutics stock price yearly change
-87.18%
year
Frequency Therapeutics key metrics
Market Cap | 10.94M |
Enterprise value | 7.60M |
P/E | -0.2 |
EV/Sales | N/A |
EV/EBITDA | -0.09 |
Price/Sales | N/A |
Price/Book | 0.24 |
PEG ratio | N/A |
EPS | -1.65 |
Revenue | N/A |
EBITDA | -58.24M |
Income | -59.31M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeFrequency Therapeutics stock price history
Frequency Therapeutics stock forecast
Frequency Therapeutics financial statements
| Dec 2022 | 0 | -17.36M | |
|---|---|---|---|
| Mar 2023 | 0 | -19.54M | |
| Jun 2023 | 0 | -10.79M | |
| Sep 2023 | 0 | -11.61M |
| 2025 | 0 | -57.3M |
|---|
Analysts Price target
Financials & Ratios estimates
| Dec 2022 | 121238000 | 52.04M | 42.93% |
|---|---|---|---|
| Mar 2023 | 101501000 | 48.25M | 47.54% |
| Jun 2023 | 79383000 | 33.97M | 42.8% |
| Sep 2023 | 46349000 | 9.61M | 20.74% |
| Dec 2022 | -15.61M | 24.56M | -833K |
|---|---|---|---|
| Mar 2023 | -14.13M | 5.49M | -2.46M |
| Jun 2023 | -8.42M | 19.21M | -11.66M |
| Sep 2023 | 392K | 0 | 0 |
Frequency Therapeutics alternative data
| Aug 2023 | 46 |
|---|---|
| Sep 2023 | 46 |
| Oct 2023 | 46 |
| Nov 2023 | 46 |
| Dec 2023 | 46 |
| Jan 2024 | 46 |
| Feb 2024 | 46 |
| Mar 2024 | 46 |
| Apr 2024 | 46 |
| May 2024 | 46 |
| Jun 2024 | 46 |
| Jul 2024 | 46 |
Frequency Therapeutics other data
6.70%
-14.45%
of FREQ is owned by hedge funds
25
-22
2.34M
-5.05M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jul 2023 | 0 | 87421 |
| Aug 2023 | 0 | 45179 |
| Nov 2023 | 0 | 2124 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | LUCCHINO DAVID L. director | Common Stock | 110 | $35.99 | $3,959 | ||
Sale | LUCCHINO DAVID L. director | Common Stock | 230 | $36.74 | $8,450 | ||
Sale | LUCCHINO DAVID L. director | Common Stock | 614 | $37.98 | $23,322 | ||
Sale | LUCCHINO DAVID L. director | Common Stock | 202 | $38.82 | $7,842 | ||
Sale | LUCCHINO DAVID L. director | Common Stock | 37 | $37.92 | $1,403 | ||
Sale | LUCCHINO DAVID L. director | Common Stock | 373 | $39.59 | $14,767 | ||
Sale | LUCCHINO DAVID L. director | Common Stock | 41 | $41.94 | $1,720 | ||
Sale | LUCCHINO DAVID L. director | Common Stock | 225 | $43.17 | $9,714 | ||
Sale | LUCCHINO DAVID L. director | Common Stock | 191 | $44.01 | $8,406 | ||
Sale | LUCCHINO DAVID L. director | Common Stock | 67 | $45.53 | $3,050 |
| Patent |
|---|
Application Filling date: 24 Sep 2021 Issue date: 18 Aug 2022 |
Application Filling date: 2 Oct 2019 Issue date: 23 Jun 2022 |
Application Filling date: 8 Apr 2020 Issue date: 9 Jun 2022 |
Application Filling date: 7 Feb 2020 Issue date: 26 May 2022 |
Application Filling date: 7 Feb 2020 Issue date: 5 May 2022 |
Application Filling date: 7 Feb 2020 Issue date: 28 Apr 2022 |
Application Filling date: 1 Oct 2021 Issue date: 31 Mar 2022 |
Grant Filling date: 19 Aug 2019 Issue date: 2 Nov 2021 |
Grant Filling date: 4 Jan 2019 Issue date: 2 Nov 2021 |
Application 1H-PYRROLE-2,5-DIONE COMPOUNDS AND METHODS OF USING THEM TO INDUCE SELF-RENEWAL OF STEM/PROGENITOR SUPPORTING CELLS Filling date: 3 Jun 2021 Issue date: 30 Sep 2021 |
-
When is Frequency Therapeutics's next earnings date?
Unfortunately, Frequency Therapeutics's (FREQ) next earnings date is currently unknown.
-
Does Frequency Therapeutics pay dividends?
No, Frequency Therapeutics does not pay dividends.
-
How much money does Frequency Therapeutics make?
Frequency Therapeutics has a market capitalization of 10.94M.
-
What is Frequency Therapeutics's stock symbol?
Frequency Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "FREQ".
-
What is Frequency Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Frequency Therapeutics?
Shares of Frequency Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Frequency Therapeutics's key executives?
Frequency Therapeutics's management team includes the following people:
- Mr. David L. Lucchino Co-Founder, Pres, Chief Executive Officer & Director(age: 56, pay: $1,100,000)
- Ms. Wendy S. Arnold Chief People Officer(age: 53, pay: $550,370)
- Mr. Peter P. Pfreundschuh Chief Financial Officer(age: 56, pay: $535,000)
-
Is Frequency Therapeutics founder-led company?
Yes, Frequency Therapeutics is a company led by its founder Mr. David L. Lucchino.
-
How many employees does Frequency Therapeutics have?
As Jul 2024, Frequency Therapeutics employs 46 workers.
-
When Frequency Therapeutics went public?
Frequency Therapeutics, Inc. is publicly traded company for more then 5 years since IPO on 3 Oct 2019.
-
What is Frequency Therapeutics's official website?
The official website for Frequency Therapeutics is frequencytx.com.
-
Where are Frequency Therapeutics's headquarters?
Frequency Therapeutics is headquartered at 75 Hayden Avenue, Lexington, MA.
-
How can i contact Frequency Therapeutics?
Frequency Therapeutics's mailing address is 75 Hayden Avenue, Lexington, MA and company can be reached via phone at +7 813154600.
Frequency Therapeutics company profile:
Frequency Therapeutics, Inc.
frequencytx.comExchange:
NASDAQ
Full time employees:
46
Industry:
Biotechnology
Sector:
Healthcare
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
75 Hayden Avenue
Lexington, MA 02421
Lexington, MA 02421
CIK: 0001703647
ISIN: US5009461089
CUSIP: 35803L108
